Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA 'Confident' Of New COVID-19 Vaccine Approvals By Year End

Executive Summary

The European drugs regulator has given an overview of progress with the assessment of new vaccine candidates, additional and booster vaccines, and the use of vaccines in younger age groups.

You may also be interested in...



Coronavirus Notebook: EMA Begins Assessing AZ’s Evusheld, Apeiron Starts Phase I Trial Of Inhaled APN01

The UK has explained its strategy for administering COVID-19 vaccines to people who have been partially immunized abroad.

EU Decision Imminent On Comirnaty Booster, Data Expected On Use In 5-11 Year Olds

The European Medicines Agency also expects to reach some conclusions on the use of MAb-based COVID-19 treatments by the end of October.

Celltrion’s COVID-19 Treatment Regdanvimab Is Approved In Korea

Celltrion continues to eye further markets for its CT-P59 regdanvimab monoclonal antibody treatment for COVID-19, especially in the EU, after winning final approval from the Korean Ministry of Food and Drug Safety.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144919

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel